文献速递脑血管病外科神经重症

多囊肾病患者动脉瘤筛查、择期治疗及蛛网膜下腔出血率的大型数据库分析

A Large Database Analysis of Rates of Aneurysm Screening, Elective Treatment, and Subarachnoid Hemorrhage in Patients With Polycystic Kidney Disease.
PubMed 文献 · Neurosurgery · 2019-01-01

该研究基于2004至2014年大型私人保险数据库,分析已知多囊肾病(PKD)患者的动脉瘤筛查、择期治疗及蛛网膜下腔出血(SAH)发生率;结果显示筛查仅选择性开展,择期治疗率超过对照组的10倍,但SAH发生率仍显著高于对照组。

要点

  • 在初诊PKD患者中,51/446(15.9%)在2年内接受了血管造影筛查。
  • PKD患者择期治疗率为82/10万患者年,对照组为7/10万患者年(P<.0001)。
  • PKD患者aSAH发生率是对照组的3.6倍(IRR 3.6,95%CI 1.7-7.4),saSAH的IRR为9.5(95%CI 3.3-27.5)。

核心结论

  • PKD患者的筛查仅选择性开展,但择期治疗率超过对照组的10倍;尽管进行了筛查和治疗,SAH发生率仍显著高于对照组。

研究设计与样本

  • 基于大型私人保险数据库的纵向关联索赔数据分析,纳入2004至2014年已知PKD患者,识别筛查、择期治疗、动脉瘤性蛛网膜下腔出血(aSAH)及已处理动脉瘤的蛛网膜下腔出血(saSAH),并与年龄和性别匹配的对照组比较。

主要发现

  • 共识别20704例诊断为PKD的患者;在初诊PKD患者中,51/446(15.9%)在2年内接受血管造影筛查。
  • PKD患者择期治疗40例,风险年48868年(82/10万患者年,95%CI 60-112);年龄和性别匹配对照组择期治疗24例,风险年349861年(7/10万患者年,95%CI 5-10,P<.0001)。
  • PKD患者aSAH入院11例(23/10万患者年,95%CI 13-41),对照组aSAH入院22例(6/10万患者年,95%CI 4-10),发生率比(IRR)为3.6(95%CI 1.7-7.4,P<.0001),合并症调整后IRR为3.1(95%CI 1.4-6.9)。
  • PKD患者saSAH发生率为16/10万患者年,对照组为2/10万患者年,IRR为9.5(95%CI 3.3-27.5,P<.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Professional societies provide conflicting guidelines on aneurysm screening in patients with polycystic kidney disease (PKD), and the rate of subarachnoid hemorrhage (SAH) is poorly understood. OBJECTIVE: To evaluate screening, elective treatment, and the rate of SAH in patients with known PKD. METHODS: We examined longitudinally linked claims data from a large private insurer, identifying screening, elective treatment, aneurysmal subarachnoid hemorrhage (aSAH) and secured aneurysmal SAH (saSAH) in 2004 to 2014 amongst patients with known PKD. RESULTS: We identified 20 704 patients diagnosed with PKD. Among patients with an initial PKD diagnosis, 51/446 (15.9%) underwent angiographic screening within 2 yr. Forty aneurysms were treated electively in 48 868 yr at risk in PKD patients (82/100K patient yr, 95% confidence interval [CI] 60-112) vs 24 elective treatments in 349 861 yr at risk in age- and sex-matched controls (7/100K patient yr, 95% CI 5-10, P < .0001). Eleven admissions for aSAH were identified in PKD patients (23/100K patient yr, 95% CI 13-41) and 22 admissions for aSAH in controls (6/100K patient yr, 95% CI 4-10), giving an incidence rate ratio (IRR) of 3.6 (95% CI 1.7-7.4, P < .0001) and a comorbidity-adjusted IRR of 3.1 (95% CI 1.4-6.9). The incidence of saSAH was proportionally even higher in PKD patients than controls, 16 vs 2/100K patient years, IRR 9.5 (95% CI 3.3-27.5, P < .0001). CONCLUSION: Screening in PKD is performed only selectively, though resulting rates of elective treatment were over 10× those of controls. Despite screening and treatment, the rate of SAH remains significantly elevated over that of controls.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Wilkinson DA, Burke JF, Nadel JL, et al. A Large Database Analysis of Rates of Aneurysm Screening, Elective Treatment, and Subarachnoid Hemorrhage in Patients With Polycystic Kidney Disease. Neurosurgery. 2019. PMID: 30476226. doi:10.1093/neuros/nyy551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。